← Back to Search

Dual PIM/FLT3 kinase inhibitor

SEL24/MEN1703 for Acute Myeloid Leukemia

Phase 1 & 2
Waitlist Available
Led By Farhad Ravandi, MD
Research Sponsored by Menarini Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from cycle 1 day 1 to final study visit (up to 30 days after last administered dose). each cycle lasts 21 days.
Awards & highlights

Study Summary

This trial is testing a new cancer drug to see if it is safe and what the maximum tolerated dose is.

Eligible Conditions
  • Acute Myeloid Leukemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from cycle 1 day 1 to final study visit (up to 30 days after last administered dose). each cycle lasts 21 days.
This trial's timeline: 3 weeks for screening, Varies for treatment, and from cycle 1 day 1 to final study visit (up to 30 days after last administered dose). each cycle lasts 21 days. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Dose limiting toxicity (DLT) evaluation
Secondary outcome measures
Safety profile of single agent SEL24/MEN1703

Trial Design

1Treatment groups
Experimental Treatment
Group I: SEL24/MEN1703Experimental Treatment1 Intervention
SEL24/MEN1703 will be given as oral capsules once daily for 14 consecutive days over a 21-day treatment cycle. Part 1: ascending dose levels (cohort) will be tested in at least 3 patients. Any cohort in which 1 patient experiences a dose-limiting toxicity will be expanded up to 6 patients. Part 2: testing at the dose of SEL24/MEN1703 which have demonstrated to be adequately tolerated in Part 1.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SEL24/MEN1703
2017
Completed Phase 2
~80

Find a Location

Who is running the clinical trial?

Menarini GroupLead Sponsor
42 Previous Clinical Trials
11,753 Total Patients Enrolled
Medpace, Inc.Industry Sponsor
94 Previous Clinical Trials
29,542 Total Patients Enrolled
TheradexIndustry Sponsor
33 Previous Clinical Trials
1,519 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
SEL24/MEN1703 in Patients With Acute Myeloid Leukemia
2017. "SEL24/MEN1703 in Patients With Acute Myeloid Leukemia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03008187.
~9 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top